Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (10613)	7/4/1999 10:44:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

The information is going to be available for some time before they get it into a peer reviewed journal or discussed at a meeting. I suppose with dozens of people knowing the results before then you are willing to wait weeks and months for the basic information? There is no rule by the FDA that shareholders can't be told something or in fact everything at once. It is logical though that if the whole world know, no peer review journal will have any interest in running the story. So the "journal" must get some kind of exclusive access to the information, to have an incentive to run the story. I would think releasing the basic details might stimulate interest in any subsequent story. Of course the companies will send copies of these stories to those who have an interest in the drugs discussed. Support the concept of limited release of the bare bones non technical data!!!!

To: Bluegreen who wrote (10613)	7/6/1999 12:25:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Resistance is futile! pslgroup.com

To: Bluegreen who wrote (10613)	7/7/1999 11:57:00 AM
From: aknahow	Respond to of 17367

Bluegreen, see you just can't leave those with no interest in XOMA in peace. Apparently there are lots of other companies with better results out there. At least that is how I am interpret Harmons's comment on the BioTransplant board. <<<<<<<n a sense, anti-CD11a modulates the risk. OTOH, there are other really strong approaches to psoriasis.>>>>>>> Partial paste of his comments on XOMA in reply to message by TexasDude, "I think." Anyone know the results of the P II or P III test of these other approaches by competitors?